Current Thoracic Surgery 2021 , Vol 6 , Issue 1
Prognostic value of Glasgow Prognostic Score in patients with non-small cell lung cancers undergoing pN2 pneumonectomy
Cemal Aker1,Celal Bugra Sezen1,Altan Ceritoglu1,Mustafa Vedat Dogru1,Yunus Aksoy1,Cem Emrah Kalafat1,Volkan Erdogu1,Levent Cansever1,Muzaffer Metin1
1Department of Thoracic Surgery, Health of Sciences University, Yedikule Chest Diseases and Thoracic Surgery Health Application and Research Center, Istanbul, Turkey DOI : 10.26663/cts.2021.0002 Viewed : 3100 - Downloaded : 1287 Background: The aim of this study was to assess the relationship between Glasgow Prognosis Score (GPS) and survival in patients who underwent pneumonectomy due to pN2 non-small cell lung cancer (NSCLC).

Materials and Methods: A total of 45 patients who were determined to have pN2 disease after pneumonectomy between 2007 and 2016 were retrospectively analyzed. The patients were assigned a GPS between 0 and 2 as follows: elevated CRP level (>1.0 mg/dL) and hypoalbuminemia (<35 mg/dL) was classified as GPS 2, elevated CRP but albumin >35 mg/dL was classified as GPS 1, and CRP <1.0 mg/dl and albumin >35 mg/dL were classified as GPS 0.

Results: Of the 45 patients included in the study, 42 (93.3%) were male and 3 (6.7%) were female. Eighteen (40%) of the patients had adenocarcinoma and 27 (60%) had squamous cell carcinoma. Skip pN2 (pN0N2) was detected in 10 patients. Mean follow-up time was 28 months. The 5-year survival rate was 40.2%. The main prognostic factors associated with survival were GPS and adjuvant therapy (p = 0.023, p = 0.001).

Conclusions: In this study, there was no relationship between N1 status and survival in pneumonectomy patients with pN2 NSCLC, whereas GPS score and adjuvant therapy were found to be prognostically significant in terms of survival. Keywords : lung carcinoma, pneumonectomy, Glasgow Prognostic Score, survival, prognosis, prognostic scores